Why Two Sigma Ventures invested in Kallyope’s $66M series B

Kallyope Inc.’s data-intensive approach to mapping the gut-brain axis led Two Sigma Ventures to join the biotech’s $66 million series B round, marking the VC’s second investment in therapeutics.

Existing investor Lux Capital led the

Read the full 359 word article

User Sign In